Gastrin exerts pleiotropic effects on human melanoma cell biology.
The effects of gastrin (G17) on the growth and migration factors of four human melanoma cell lines (HT-144, C32, G-361, and SKMEL-28) were investigated. The expression patterns of cholecystokinin (CCK)(A), CCK(B), and CCK(C) gastrin receptors were investigated in these cells and in seven clinical samples by means of reverse transcription polymerase chain reaction. Melanoma cells appear to express mRNA for CCK(C) receptors, but not for CCK(A) or CCK(B) receptors. Although gastrin does not significantly modify the growth characteristics of the cell lines under study, it significantly modifies their cell migration characteristics. These modifications occur at adhesion level by modifying the expression levels of alpha(v) and beta3 integrins, at motility level by modifying the organization of the actin cytoskeleton, and at invasion level by modifying the expression levels of matrix metalloproteinase 14. We recently demonstrated the presence of CCK(B) receptors in mouse endothelial cells involved in glioblastoma neoangiogenesis. Chronic in vivo administration of a selective CCK(B) receptor antagonist to mice bearing xenografts of human C32 melanoma cells significantly decreased levels of neoangiogenesis, resulting in considerable delays in the growth of these C32 xenografts. In conclusion, our study identifies the pleiotropic effects of gastrin on melanoma cell biology.
Mathieu
Véronique
V
Laboratory of Toxicology, Institute of Pharmacy, Free University of Brussels (ULB), Brussels, Belgium.
Mijatovic
Tatjana
T
van Damme
Marc
M
Kiss
Robert
R
D000199:Actins / Q000737:chemistry; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002465:Cell Movement; D002766:Cholecystokinin / Q000378:metabolism; D002945:Cisplatin / Q000494:pharmacology; D003599:Cytoskeleton / Q000378:metabolism; D017931:DNA Primers / Q000737:chemistry; D018076:DNA, Complementary / Q000378:metabolism; D003606:Dacarbazine / Q000494:pharmacology; D005434:Flow Cytometry; D005755:Gastrins / Q000737:chemistry / Q000378:metabolism / Q000502:physiology*; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D008545:Melanoma / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D009361:Neoplasm Invasiveness; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D020411:Oligonucleotide Array Sequence Analysis; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000378:metabolism; D043887:Receptor, Cholecystokinin B / Q000378:metabolism; D011949:Receptors, Cholecystokinin / Q000737:chemistry; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014945:Wound Healing
D000199:Actins; D000970:Antineoplastic Agents; D017931:DNA Primers; D018076:DNA, Complementary; D005755:Gastrins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D003606:Dacarbazine; D002766:Cholecystokinin; D011065:Poly(ADP-ribose) Polymerases; D002945:Cisplatin